PDA

View Full Version : SNSS - Sunesis Pharmaceuticals Inc.



Adrianduh
08-07-2015,
Oh boy, news today loooks good on this one, and with the tiny float it should FLY

Sunesis Pharmaceuticals 4Q Rev $4.52M Vs $3.87M, +17%

SOUTH SAN FRANCISCO, Calif., March 24 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS - News), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics, today reported financial results for the quarter and fiscal year ended December 31, 2005. Total revenues for the fourth quarter were $4.5 million, with a net loss of $5.3 million. Total revenues for 2005 were $16.5 million, with a net loss of $27.5 million. As of December 31, 2005, cash, cash equivalents and marketable securities totaled $48.3 million and debt totaled $2.4 million.

Adjistyync
08-07-2015,
Sunesis Pharma reports positive initial results from Phase 2 small cell lung cancer trial with SNS-595 (SNSS) 4.66 : Co announces that the co will advance the small-cell lung cancer trial in treatment-sensitive patients to Stage 2. The co reported initial results from the first stages of two Phase 2 clinical trials of SNS-595, a novel cell-cycle inhibitor, in first-line relapsed/refractory small cell and non-small cell lung cancers. Anti-tumor activity was observed, including evidence of stable disease, minor responses and partial responses reported in one arm of the small cell lung cancer study, and minor and mixed responses and stable disease in the non-small cell lung cancer trial.

Adriannep
08-08-2015,
SNSS Sunesis Pharm....just want everyone to start diggin
Looks like it might be a sleeper they have 2 phase II that look like they are close to moving to III. I have no idea how far away the are...I couldnt tell ya how real they are right now.....looking for more DD now. They did pull out of a study not to long ago 12/23/08
They look to be stable at this pps/volume low imo

adolume
08-08-2015,
Sunesis Reports Financial Results for the Third Quarter 2008
Download PDF
- Conference Call Scheduled for Today at 11:00 a.m. EST -

SOUTH SAN FRANCISCO, Calif., Nov 04, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the third quarter ending September 30, 2008.

Total revenue for the third quarter of 2008 was $0.5 million, with a net loss of $7.1 million. As of September 30, 2008, cash, cash equivalents and marketable securities totaled $18.3 million, and debt totaled $1.6 million.

"In the third quarter of this year, we continued to make significant progress moving voreloxin forward in the clinic," said Dan Swisher, Chief Executive Officer of Sunesis. "Enrollment in each of our ongoing ovarian and acute myeloid leukemia (AML) studies is strong, and we look forward to presenting new results from the AML studies at ASH in December."

I cant find any Dec announcement